Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Respiratory Tract Diseases 1Neoplasms 1Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Pemetrexed 8Spinal Puncture 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 4aflutinib 3Trastuzumab 3Bevacizumab 3trastuzumab deruxtecan 2pembrolizumab 2osimertinib 2Radiotherapy, Intensity-Modulated 2tucatinib 1toripalimab 1sintilimab 1sacituzumab govitecan 1pertuzumab 1peginterferon alfa-2b 1lorlatinib 1lenvatinib 1azeliragon 1avelumab 1adavosertib 1Temozolomide 1Referral and Consultation 1Radiosurgery 1Radiation 1Probability 1Physical Examination 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × AZD3759 × 1 year × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡